| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| RDY | Dr. Reddy's Laboratories Ltd | $35.7 | $5.93B | N/A |
Zynerba Releases Data on Epilepsy Candidate, Stock Down
http://www.zacks.com/stock/news/526215/zynerba-releases-data-on-epilepsy-candidate-stock-down?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-526215
Sep 19, 2019 - Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
0
The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power
http://www.zacks.com/stock/news/532018/the-zacks-analyst-blog-highlights-dr-reddys-wns-and-azure-power?cid=CS-ZC-FT-press_releases-532018
Sep 23, 2019 - The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power
0
Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen
http://www.zacks.com/stock/news/543304/mylan-myl-to-pay-%2430m-to-settle-sec-charges-for-epipen?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-543304
Sep 30, 2019 - Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.
0
New Strong Sell Stocks for November 11th
http://www.zacks.com/stock/news/614102/new-strong-sell-stocks-for-november-11th?cid=CS-ZC-FT-tale_of_the_tape|new_zacks_#5_rank_stocks-614102
Nov 11, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
0
Top Ranked Momentum Stocks to Buy for September 17th
http://www.zacks.com/commentary/522889/top-ranked-momentum-stocks-to-buy-for-september-17th?cid=CS-ZC-FT-zacks_#1_rank_additions-522889
Sep 17, 2019 - Top Ranked Momentum Stocks to Buy for September 17th
0
J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use
http://www.zacks.com/stock/news/526368/jjs-prostate-cancer-drug-gets-fda-nod-for-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-526368
Sep 19, 2019 - J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
0
Is it Apt to Foray Into the Indian Stock Market?: An Analysis
http://www.zacks.com/stock/news/527926/is-it-apt-to-foray-into-the-indian-stock-market-an-analysis?cid=CS-ZC-FT-analyst_blog|investment_ideas-527926
Sep 20, 2019 - The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.
0
Dr. Reddy's Laboratories Ltd (RDY) CEO Erez Israeli on Q2 2020 Results - Earnings Call Transcript
https://seekingalpha.com/article/4301629-dr-reddys-laboratories-ltd-rdy-ceo-erez-israeli-q2-2020-results-earnings-call-transcript?source=feed_tag_india
Nov 01, 2019 - Dr. Reddy's Laboratories Ltd (NYSE:RDY) Q2 2020 Earnings Conference Call November 01, 2019, 09:00 ET Company Participants Amit Agarwal - Director, Finance, FP&A and IR Saumen Chakraborty - Preside
0
Pages: 1
Page 1